Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 3300 entries
Sorted by: Best Match Show Resources per page
[Analysis of results of a trial using the subject as its own control with a criterion of binary response].

Journal de pharmacologie

Pejovic MH, Rey A, Kramar A, Doyon F, Com-Nougué C.
PMID: 3560965
J Pharmacol. 1986 Oct-Dec;17(4):497-507.

The two-period cross-over design is often used in clinical trials in which subjects serve as their own controls. This procedure may produce a more powerful test, but also may produce bias due to carry-over effects. Three tests have been...

Cite
Pejovic MH, Rey A, Kramar A, et al. Analyse des résultats d'un essai utilisant le sujet comme son propre témoin avec un critère de jugement binaire. [Analysis of results of a trial using the subject as its own control with a criterion of binary response]. J Pharmacol. 1986;17(4):497-507
Pejovic, M. H., Rey, A., Kramar, A., Doyon, F., & Com-Nougué, C. (1986). Analyse des résultats d'un essai utilisant le sujet comme son propre témoin avec un critère de jugement binaire. [Analysis of results of a trial using the subject as its own control with a criterion of binary response]. Journal de pharmacologie, 17(4), 497-507.
Pejovic, M H, et al. "Analyse des résultats d'un essai utilisant le sujet comme son propre témoin avec un critère de jugement binaire." [Analysis of results of a trial using the subject as its own control with a criterion of binary response]. Journal de pharmacologie vol. 17,4 (1986): 497-507.
Pejovic MH, Rey A, Kramar A, Doyon F, Com-Nougué C. Analyse des résultats d'un essai utilisant le sujet comme son propre témoin avec un critère de jugement binaire. [Analysis of results of a trial using the subject as its own control with a criterion of binary response]. J Pharmacol. 1986 Oct-Dec;17(4):497-507. French. PMID: 3560965.
Copy Download .nbib Format: NLM
Life-threatening bradyarrhythmia with oral phenytoin overdose.

Journal of pharmacology & pharmacotherapeutics

Srinivasan G, Wyawahare M, Mathen PG, Subrahmanyam DK.
PMID: 26312007
J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):179-81. doi: 10.4103/0976-500X.162017.

We report a case of a 41-year-old lady, who developed severe hypotension and sinus bradycardia, following oral consumption of 20 g of phenytoin and 500 mg of glibenclamide. She required high dose of inotropes and a temporary transvenous pacer...

Cite
Srinivasan G, Wyawahare M, Mathen PG, et al. Life-threatening bradyarrhythmia with oral phenytoin overdose. J Pharmacol Pharmacother. 2015;6(3):179-81doi: 10.4103/0976-500X.162017.
Srinivasan, G., Wyawahare, M., Mathen, P. G., & Subrahmanyam, D. K. (2015). Life-threatening bradyarrhythmia with oral phenytoin overdose. Journal of pharmacology & pharmacotherapeutics, 6(3), 179-81. https://doi.org/10.4103/0976-500X.162017
Srinivasan, Giridharan, et al. "Life-threatening bradyarrhythmia with oral phenytoin overdose." Journal of pharmacology & pharmacotherapeutics vol. 6,3 (2015): 179-81. doi: https://doi.org/10.4103/0976-500X.162017
Srinivasan G, Wyawahare M, Mathen PG, Subrahmanyam DK. Life-threatening bradyarrhythmia with oral phenytoin overdose. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):179-81. doi: 10.4103/0976-500X.162017. PMID: 26312007; PMCID: PMC4544145.
Copy Download .nbib Format: NLM
Complete resistance after maximal dose of rocuronium.

Journal of pharmacology & pharmacotherapeutics

Capuano A, Sullo MG, Rafaniello C, Sportiello L, Fusco P, De Vizia M, Ferraro F.
PMID: 26312006
J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):175-8. doi: 10.4103/0976-500X.162012.

Rocuronium is a non-depolarizing neuromuscular blocking agent (NDNMBA), employed in the clinic as an adjunct to general anesthesia to facilitate tracheal intubation rapid sequence, and to provide skeletal muscle relaxation during surgery. Many cases of resistance to neuromuscular blocking...

Cite
Capuano A, Sullo MG, Rafaniello C, et al. Complete resistance after maximal dose of rocuronium. J Pharmacol Pharmacother. 2015;6(3):175-8doi: 10.4103/0976-500X.162012.
Capuano, A., Sullo, M. G., Rafaniello, C., Sportiello, L., Fusco, P., De Vizia, M., & Ferraro, F. (2015). Complete resistance after maximal dose of rocuronium. Journal of pharmacology & pharmacotherapeutics, 6(3), 175-8. https://doi.org/10.4103/0976-500X.162012
Capuano, Annalisa, et al. "Complete resistance after maximal dose of rocuronium." Journal of pharmacology & pharmacotherapeutics vol. 6,3 (2015): 175-8. doi: https://doi.org/10.4103/0976-500X.162012
Capuano A, Sullo MG, Rafaniello C, Sportiello L, Fusco P, De Vizia M, Ferraro F. Complete resistance after maximal dose of rocuronium. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):175-8. doi: 10.4103/0976-500X.162012. PMID: 26312006; PMCID: PMC4544144.
Copy Download .nbib Format: NLM
Preface. Novel targets and drugs to prevent atherogenesis and its consequences.

European journal of pharmacology

Riksen NP, Rongen GA.
PMID: 26370897
Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042.

No abstract available.

Cite
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015;763:1-2doi: 10.1016/j.ejphar.2015.08.042.
Riksen, N. P., & Rongen, G. A. (2015). Preface. Novel targets and drugs to prevent atherogenesis and its consequences. European journal of pharmacology, 7631-2. https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen, Niels P, and Rongen, Gerard A. "Preface. Novel targets and drugs to prevent atherogenesis and its consequences." European journal of pharmacology vol. 763 (2015): 1-2. doi: https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042. PMID: 26370897.
Copy Download .nbib Format: NLM
The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy.

Journal of pharmacology & pharmacotherapeutics

Patel L, Thaker A.
PMID: 26311998
J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):147-53. doi: 10.4103/0976-500X.162014.

INTRODUCTION: To investigate the actions of adenosine A2B receptor modulators on VEGF and NO levels in CsA nephropathy.MATERIALS AND METHODS: Nephropathy was induced by administrating 25 mg/kg (s.c) of CsA for 5 weeks. The VEGF and NO levels were...

Cite
Patel L, Thaker A. The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy. J Pharmacol Pharmacother. 2015;6(3):147-53doi: 10.4103/0976-500X.162014.
Patel, L., & Thaker, A. (2015). The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy. Journal of pharmacology & pharmacotherapeutics, 6(3), 147-53. https://doi.org/10.4103/0976-500X.162014
Patel, Leena, and Thaker, Aswin. "The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy." Journal of pharmacology & pharmacotherapeutics vol. 6,3 (2015): 147-53. doi: https://doi.org/10.4103/0976-500X.162014
Patel L, Thaker A. The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):147-53. doi: 10.4103/0976-500X.162014. PMID: 26311998; PMCID: PMC4544136.
Copy Download .nbib Format: NLM
Intestinal pseudo-obstruction following oral baclofen: An unusual complication.

Journal of pharmacology & pharmacotherapeutics

Karthikeyan VS, Senthilkumaran K, Easwaran B, Rajbhaskar R.
PMID: 26312004
J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):169-71. doi: 10.4103/0976-500X.162010.

Baclofen is a gamma- aminobutyric acid B (GABA B) agonist used for the management of spasticity associated with spinal cord injury. Oral baclofen might cause constipation, but intestinal pseudo-obstruction is very rare. We report a 50-year-old male with spasticity...

Cite
Karthikeyan VS, Senthilkumaran K, Easwaran B, et al. Intestinal pseudo-obstruction following oral baclofen: An unusual complication. J Pharmacol Pharmacother. 2015;6(3):169-71doi: 10.4103/0976-500X.162010.
Karthikeyan, V. S., Senthilkumaran, K., Easwaran, B., & Rajbhaskar, R. (2015). Intestinal pseudo-obstruction following oral baclofen: An unusual complication. Journal of pharmacology & pharmacotherapeutics, 6(3), 169-71. https://doi.org/10.4103/0976-500X.162010
Karthikeyan, Vilvapathy Senguttuvan, et al. "Intestinal pseudo-obstruction following oral baclofen: An unusual complication." Journal of pharmacology & pharmacotherapeutics vol. 6,3 (2015): 169-71. doi: https://doi.org/10.4103/0976-500X.162010
Karthikeyan VS, Senthilkumaran K, Easwaran B, Rajbhaskar R. Intestinal pseudo-obstruction following oral baclofen: An unusual complication. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):169-71. doi: 10.4103/0976-500X.162010. PMID: 26312004; PMCID: PMC4544142.
Copy Download .nbib Format: NLM
Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.

Journal of pharmacology & pharmacotherapeutics

Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK.
PMID: 26312011
J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):188-92. doi: 10.4103/0976-500X.162015.

Opioid-induced constipation (OIC) is one of the most troublesome and the most common effects of opioid use leading to deterioration in quality of life of the patients and also has potentially deleterious repercussions on adherence and compliance to opioid...

Cite
Anantharamu T, Sharma S, Gupta AK, et al. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015;6(3):188-92doi: 10.4103/0976-500X.162015.
Anantharamu, T., Sharma, S., Gupta, A. K., Dahiya, N., Singh Brashier, D. B., & Sharma, A. K. (2015). Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. Journal of pharmacology & pharmacotherapeutics, 6(3), 188-92. https://doi.org/10.4103/0976-500X.162015
Anantharamu, Tejus, et al. "Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation." Journal of pharmacology & pharmacotherapeutics vol. 6,3 (2015): 188-92. doi: https://doi.org/10.4103/0976-500X.162015
Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):188-92. doi: 10.4103/0976-500X.162015. PMID: 26312011; PMCID: PMC4544149.
Copy Download .nbib Format: NLM
A case of losartan-induced severe hyponatremia.

Journal of pharmacology & pharmacotherapeutics

Das S, Bandyopadhyay S, Ramasamy A, Prabhu VV, Pachiappan S.
PMID: 26816476
J Pharmacol Pharmacother. 2015 Oct-Dec;6(4):219-21. doi: 10.4103/0976-500X.171880.

This case report outlines a very rare case of losartan-induced severe hyponatremia in a 73-year-old type 2 diabetic patient. The patient was initiated with 50 mg daily oral losartan monotherapy for newly diagnosed moderate hypertension. After 3.5 months of...

Cite
Das S, Bandyopadhyay S, Ramasamy A, et al. A case of losartan-induced severe hyponatremia. J Pharmacol Pharmacother. 2015;6(4):219-21doi: 10.4103/0976-500X.171880.
Das, S., Bandyopadhyay, S., Ramasamy, A., Prabhu, V. V., & Pachiappan, S. (2015). A case of losartan-induced severe hyponatremia. Journal of pharmacology & pharmacotherapeutics, 6(4), 219-21. https://doi.org/10.4103/0976-500X.171880
Das, Saibal, et al. "A case of losartan-induced severe hyponatremia." Journal of pharmacology & pharmacotherapeutics vol. 6,4 (2015): 219-21. doi: https://doi.org/10.4103/0976-500X.171880
Das S, Bandyopadhyay S, Ramasamy A, Prabhu VV, Pachiappan S. A case of losartan-induced severe hyponatremia. J Pharmacol Pharmacother. 2015 Oct-Dec;6(4):219-21. doi: 10.4103/0976-500X.171880. PMID: 26816476; PMCID: PMC4714391.
Copy Download .nbib Format: NLM
Successful management of malignant hyperpyrexia syndrome in a pediatric patient: What to do when dantrolene is not available?.

Journal of pharmacology & pharmacotherapeutics

Gupta P, Kamal G, Gupta M.
PMID: 26816473
J Pharmacol Pharmacother. 2015 Oct-Dec;6(4):211-3. doi: 10.4103/0976-500X.171873.

Malignant hyperpyrexia syndrome (MHS) is a rare entity and may not be encountered by the anaesthesiologists throughout their professional career. Whenever it manifests can be a challenging task to manage and prove to be fatal when a timely diagnosis...

Cite
Gupta P, Kamal G, Gupta M. Successful management of malignant hyperpyrexia syndrome in a pediatric patient: What to do when dantrolene is not available?. J Pharmacol Pharmacother. 2015;6(4):211-3doi: 10.4103/0976-500X.171873.
Gupta, P., Kamal, G., & Gupta, M. (2015). Successful management of malignant hyperpyrexia syndrome in a pediatric patient: What to do when dantrolene is not available?. Journal of pharmacology & pharmacotherapeutics, 6(4), 211-3. https://doi.org/10.4103/0976-500X.171873
Gupta, Priyanka, et al. "Successful management of malignant hyperpyrexia syndrome in a pediatric patient: What to do when dantrolene is not available?." Journal of pharmacology & pharmacotherapeutics vol. 6,4 (2015): 211-3. doi: https://doi.org/10.4103/0976-500X.171873
Gupta P, Kamal G, Gupta M. Successful management of malignant hyperpyrexia syndrome in a pediatric patient: What to do when dantrolene is not available?. J Pharmacol Pharmacother. 2015 Oct-Dec;6(4):211-3. doi: 10.4103/0976-500X.171873. PMID: 26816473; PMCID: PMC4714388.
Copy Download .nbib Format: NLM
Declaration.

British journal of pharmacology

[No authors listed]
PMID: 26814172
Br J Pharmacol. 2016 Feb;173(3):628. doi: 10.1111/bph.13405.

No abstract available.

Cite
Declaration. Br J Pharmacol. 2016;173(3):628doi: 10.1111/bph.13405.
(2016). Declaration. British journal of pharmacology, 173(3), 628. https://doi.org/10.1111/bph.13405
"Declaration." British journal of pharmacology vol. 173,3 (2016): 628. doi: https://doi.org/10.1111/bph.13405
Declaration. Br J Pharmacol. 2016 Feb;173(3):628. doi: 10.1111/bph.13405. PMID: 26814172; PMCID: PMC4728420.
Copy Download .nbib Format: NLM
Correction to "Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells".

The Journal of pharmacology and experimental therapeutics

[No authors listed]
PMID: 27190171
J Pharmacol Exp Ther. 2016 Jun;357(3):619. doi: 10.1124/jpet.113.205120err.

No abstract available.

Cite
Correction to "Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells". J Pharmacol Exp Ther. 2016;357(3):619doi: 10.1124/jpet.113.205120err.
(2016). Correction to "Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells". The Journal of pharmacology and experimental therapeutics, 357(3), 619. https://doi.org/10.1124/jpet.113.205120err
"Correction to "Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells"." The Journal of pharmacology and experimental therapeutics vol. 357,3 (2016): 619. doi: https://doi.org/10.1124/jpet.113.205120err
Correction to "Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells". J Pharmacol Exp Ther. 2016 Jun;357(3):619. doi: 10.1124/jpet.113.205120err. PMID: 27190171.
Copy Download .nbib Format: NLM
Learning Pharmacology by Metaphors: A Tale of Beta-blockers.

Journal of pharmacology & pharmacotherapeutics

Khilnani G, Khilnani AK, Thaddanee R.
PMID: 29472749
J Pharmacol Pharmacother. 2017 Oct-Dec;8(4):172-175. doi: 10.4103/jpp.JPP_104_17.

No abstract available.

Cite
Khilnani G, Khilnani AK, Thaddanee R. Learning Pharmacology by Metaphors: A Tale of Beta-blockers. J Pharmacol Pharmacother. 2017;8(4):172-175doi: 10.4103/jpp.JPP_104_17.
Khilnani, G., Khilnani, A. K., & Thaddanee, R. (2017). Learning Pharmacology by Metaphors: A Tale of Beta-blockers. Journal of pharmacology & pharmacotherapeutics, 8(4), 172-175. https://doi.org/10.4103/jpp.JPP_104_17
Khilnani, Gurudas, et al. "Learning Pharmacology by Metaphors: A Tale of Beta-blockers." Journal of pharmacology & pharmacotherapeutics vol. 8,4 (2017): 172-175. doi: https://doi.org/10.4103/jpp.JPP_104_17
Khilnani G, Khilnani AK, Thaddanee R. Learning Pharmacology by Metaphors: A Tale of Beta-blockers. J Pharmacol Pharmacother. 2017 Oct-Dec;8(4):172-175. doi: 10.4103/jpp.JPP_104_17. PMID: 29472749; PMCID: PMC5820747.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 3300 entries